PGP. Arsène Der Garabedian

P. Arsène Der Garabedian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


P. Arsène Der Garabedian has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Serge Christmann-Franck

    Département de Biologie et Pharmacologie Structurales, CNRS UMR 8113, Institut Gustave Roussy et ENS Cachan, 61 Avenue du Président Wilson, 94235 Cachan Cedex, France

    2 shared publications
  • Serge Fermandjian

    Département de Biologie et Pharmacologie Structurales, CNRS UMR 8113, Institut Gustave Roussy et ENS Cachan, 61 Avenue du Président Wilson, 94235 Cachan Cedex, France

    2 shared publications
  • Gilles Mirambeau

    1 shared publication
  • Gilles Mirambeau

    Unitat de Recerca de la Sida, Fundació Clinic-IDIBAPS, Pare Cientific de Barcelona, Universidad de Barcelona, Barcelona, España

    1 shared publication
  • Jacqueline J. Vermeersch

    Biochimie des Signaux Régulateurs Cellulaires et Moléculaires, Université Pierre et Marie Curie, CNRS FRE 2621, 96 Boulevard Raspail, 75006 Paris, France

    1 shared publication
  • Leon V. Karabashyan

    1 shared publication

Latest Publications

  • Molecular modelling studies on the interactions of human DNA topoisomerase IB with pyridoxal-compounds

    by Serge Christmann-Franck, Serge Fermandjian, Gilles Mirambeau, P. Arsène Der Garabedian


  • Open Access

    Pyridoxal 5'-phosphate inactivates DNA topoisomerase IB by modifying the lysine general acid

    by Jacqueline J. Vermeersch, Serge Christmann-Franck, Leon V. Karabashyan, Serge Fermandjian, Gilles Mirambeau, P. Arsène Der Garabedian

    The present results demonstrate that pyridoxal, pyridoxal 5′-phosphate (PLP) and pyridoxal 5′-diphospho-5′-adenosine (PLP-AMP) inhibit Candida guilliermondii and human DNA topoisomerases I in forming an aldimine with the ϵ-amino group of an active site lysine. PLP acts as a competitive inhibitor of C.guilliermondii topoisomerase I (Ki = 40 μM) that blocks the cleavable complex formation. Chemical reduction of PLP-treated enzyme reveals incorporation of 1 mol of PLP per mol of protein. The limited trypsic proteolysis releases a 17 residue peptide bearing a lysine-bound PLP (KPPNTVIFDFLGK*DSIR). Targeted lysine (K*) in C.guilliermondii topoisomerase I corresponds to that found in topoisomerase I of Homo sapiens (K532), Candida albicans (K468), Saccharomyces cerevisiae (K458) and Schizosaccharomyces pombe (K505). In the human enzyme, K532, belonging to the active site acts as a general acid catalyst and is therefore essential for activity. The spatial orientation of K532–PLP within the active site was approached by molecular modeling using available crystallographic data. The PLP moiety was found at close proximity of several active residues. PLP could be involved in the cellular control of topoisomerases IB. It constitutes an efficient tool to explore topoisomerase IB dynamics during catalysis and is also a lead for new drugs that trap the lysine general acid.